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Abstract 
Background: Premenstrual syndrome (PMS) refers to a set of physical, 
psychological or behavioral symptoms occurring in ovulation cycles, 
which in some ways disturbs a person's activities. The aim of study was 
to investigate the relationship between previous use of contraceptive 
pills and psychological symptoms of PMS. 
Methods: This cross-sectional study was conducted among all female 
students of Shahroud university of medical sciences. Samples were 
selected by simple census and were provided a standard questionnaire 
for measuring the PMS. Significant level was set at 0.05. 
Results: 65.5% of the participants had some degree of PMS. The use of 
OCP significantly reduced some PMS related symptoms such as 
depression (Pvalue = 0.039), sadness (Pvalue = 0.012), sobering up 
(Pvalue = 0.003) and anger (Pvalue = 0.032). 
Conclusions: The results of this study showed the use of OCP can 
clearly and significantly reduce some of the symptoms associated with 
PMS, such as depression, sadness and sobering up and anger. 
Keywords: PMS, OCP, Psychiatry symptoms. 
*Corresponding to: MB Sohrabi, Email: mb.sohrabi@yahoo.com 
Please cite this paper as: Majdi M, Farjamfar M, Zolfaghari P, 
Mirghasemi M, Sohrabi MB. The evaluation of relationship between oral 
contraceptive usages with psychiatry symptoms of premenstrual syndrome. 
Int J Health Stud 2019;5(4):26-29  
Introduction 
Premenstrual syndrome (PMS), a persistent pattern is 
limited to physical and emotional symptoms which occur only 
during the luteal phase of the menstrual cycle, which are of 
sufficient intensity to interfere with some aspects of life and 
happen at least 2 consecutive cycles.1 Symptoms begin after 
ovulation and intensify one week before menstruation and then 
gradually decreases.2 Only a small percentage of women (2 to 
5%) have PMS syndrome which can be separated from the 
normal discomfort associated with menstruation in healthy 
women. Although the syndrome is one of the most common 
diseases in the world, the actual prevalence is difficult to 
calculate and the main reason for this is the wide discrepancy 
in definitions and diagnostic criteria.3 However, it is estimated 
that 80% of women in reproductive age experience some of the 
symptoms of this syndrome before menstruation and in 5% of 
people, the symptoms are severe, which causes a widespread 
dysfunction.3-5 At least 5 marks should be available to prove 
mood changes that including very depressed mood; impressive 
anxiety; intense mood swings; intense or persistent anger; 
indifference to everyday activities; drowsiness; severe loss of 
appetite; sweaty or sleeplessness; feeling broken and frustrated 
and physical symptoms.6 Reducing exposure to estrogen is 
associated with mood disorders which are due to the decrease 
in serotonin activity. Thus, one of the PMS therapies is a 
combination of oral contraceptive pills (OCP). These pills 
contain estrogen and progesterone that dosage in the 
monophasic tablets is constant, but the dosage of multiphasic 
tablets varies over a cycle. These pills also affect dysmenorrhea 
and menorrhagia. Symptoms of this syndrome are divided into 
two parts: physical symptoms and mood symptoms, each of 
them is different in different people.7 Some research has the 
positive impact of OCP in reducing and controlling the 
symptoms of PMS has been mentioned and some research has 
also ruled out this effect. Regarding physical symptoms, OCP 
has had many successes in controlling these symptoms and in a 
large number of articles this positive impact is mentioned but 
regarding the control of mood and psychological symptoms, 
the studies performed are not very transparent and there are 
many contradictions in their results.8-10 Because the prevalence 
of OCP in the community is high and the complications of 
PMS for many women, especially female workers or students 
have been intolerable and they have been distracting them for a 
long time and considering the controversy about the effect of 
OCP on the reduction of mood symptoms in PMS, this research 
is aimed at the evaluation of relationship between OCP usages 
with psychiatry symptoms of PMS among female students of 
Shahroud university of medical sciences during the year 2017. 
Materials and Methods 
This cross-sectional study was conducted among all female 
students of Shahroud university of medical sciences who were 
volunteering to participate in the project between January and 
December 2017. Samples were selected as a simple census (and 
completed to sample size) and after fully justifying them and 
expressing the purpose and syntax of execution, the standard 
questionnaire for measuring the PMS was provided to them and 
after it was completed, it was collected. The questionnaire 
included two parts: the first part contains demographic 
information (age, marital status), the use or non-use of OCP, 
and the second part included 30 questions that measured the 
frequency and severity of symptoms of PMS. 25 questions 
about PMS physical and mental symptoms and 5 questions 
about PMS effect on occupational, social and family 
relationships that designed according to DSMIV1 criteria. For 
study the symptoms and abnormalities of premenstrual 
syndrome was used than PMS symptoms questionnaire 
according to PSST (premenstrual screening tool) which 
included 25 questions, designed and people were asked to rate 
the severity of symptoms and disorders according to a 4-degree 
Majdi et al 
 
International Journal of Health Studies 2019;5(4)       |        27 
scale (1 = at all, 2 = low, 3 = average, and 4 = high) mark in the 
table. Individuals who responded to the symptoms mentioned 
in the questionnaire responded to at least 5 questions (of 
course, one item should be from questions 1 through 4) was 
named PMS and people who answered at least 2 questions and 
3 questions answered moderate or severe (of course, one 
answer should be from questions 1 through 4 and one 
responded to questions of functional impairment) hey were 
diagnosed as mild premenstrual dysfunction. Then, according 
to participants' response to the history of taking or not taking 
OCP, the subjects were divided into case and control groups, 
and according to the points obtained from the questionnaire 
questions above, the severity of the complications and 
symptoms of PMS is clear and the two groups were compared.  
Descriptive statistics including mean and standard 
deviation, as well as relative frequency were used to describe 
the data. To examine the relationships and comparisons 
between the two groups was used the chi-square test and 
multivariate logistic regression were used to evaluate the odds 
of each of the variables. All analyses were performed using 
SPSS software version 16 and a significant level (Pvalue < 
0.05). Sample size using Epi info 7.2 at a significant level of 
5% and a power of 80%, equal to 190 people in the case group 
and 100 people in the control group with a total of 290 people. 
This study was reviewed and approved with the ethics board 
of Shahroud university of medical sciences (code number: 
IR.SHMU.REC.1396.19). The essential information and the 
objectives of the study were explained to the patients and written 
informed consent was obtained for participation in the study. 
Results 
Of the 290 participants, 190 cases had a history of 
symptoms of PMS which of them, 190 cases had a history of 
using OCP (case group) and 100 subjects no history of using 
OCP (control group). Regarding the severity of PMS, 93 
(48.8%) were mild, 66 (34.7%) were moderate and 31 (16.5%) 
had a severe type of syndrome that there was no significant 
difference between the two groups. The mean age of the 
participants was 22.83 ± 3.35 years. There was no significant 
difference between the mean ages of the two groups. The mean 
BMI of the girls was 24.28 ± 4.58 kg/m2 that there was no 
significant difference between the two groups. The results of 
the mental symptoms of contributors in both groups are shown 
in table 1. The average score of PMS mental syndrome is in the 
case group was 29.69 ± 14.11and in the control group 
was43.37 ± 21.52 which was a significant increase in the case 
group (Pvalue < 0.001). The average score of the PMS 
questionnaire is shown in table 2. 
Table 1. Frequency distribution of the two groups in terms of psychological symptoms of premenstrual syndrome 
psychological symptoms 
Case group 
Number (%) 
Control group 
Number (%) 
Total 
Number (%) 
Pvalue 
Depression 
Positive 
Negative 
 
84(84) 
16(16) 
 
82(91.1) 
8(8.9) 
 
166(87.4) 
24(12.6) 
 
0.039 
Sad and crying 
Positive 
Negative  
 
87(87) 
13(13) 
 
87(96.7) 
3(3.3) 
 
174(91.6) 
16(8.4) 
 
0.012 
Fatigue 
Positive 
Negative 
 
91(91) 
9(9) 
 
84(93.3) 
6(6.7) 
 
175(92.1) 
15(7.9) 
 
0.417 
Disappointment 
Positive 
Negative 
 
85(85) 
15(15) 
 
78(86.7) 
12(13.3) 
 
163(85.8) 
27(14.2) 
 
0.378 
Worthless 
Positive 
Negative 
 
75(75) 
25(25) 
 
69(76.7) 
21(23.3) 
 
144(75.8) 
46(24.2) 
 
0.109 
Stress 
Positive 
Negative 
 
92(92) 
8(8) 
 
83(92.2) 
7(7.8) 
 
175(92.1) 
15(7.9) 
 
0.762 
Disquietude 
Positive 
Negative 
 
75(75) 
25(25) 
 
78(86.7) 
12(13.3) 
 
153(80.5) 
37(19.5) 
 
0.010 
Sobering up 
Positive 
Negative 
 
86(86) 
14(14) 
 
85(94.4) 
5(5.6) 
 
171(90) 
19(10) 
 
0.003 
Impatience 
Positive 
Negative 
 
96(96) 
4(4) 
 
85(94.4) 
5(5.6) 
 
181(95.3) 
9(4.7) 
 
0.056 
Decentralization 
Positive 
Negative 
 
93(93) 
7(7) 
 
80(88.9) 
10(11.1) 
 
173(91.1) 
17(8.9) 
 
0.216 
Changing appetite 
Positive 
Negative 
 
94(94) 
6(6) 
 
83(92.2) 
7(7.8) 
 
177(93.2) 
13(6.8) 
 
0.080 
Changing in sleep pattern 
Positive 
Negative 
 
82(82) 
18(18) 
 
80(88.9) 
10(11.1) 
 
162(85.3) 
28(14.7) 
 
0.378 
Anger 
Positive 
Negative 
 
78(78) 
22(22) 
 
83(92.2) 
7(7.8) 
 
161(84.7) 
29(15.3) 
 
0.032 
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Table 2. The average score of the PMS questionnaire in two groups according to total score and the score of the psychological symptoms 
score of the PMS questionnaire Case group Control group Total girls Pvalue 
Average total rating  51.25 ± 14.09 67.64 ± 21.34 58.71 ± 18.62 0.001 
Average rating for mental disorders 29.69 ± 14.11 43.37 ± 21.52 34.47 ± 18.43 0.001 
 
Discussion 
The results of this study showed that the use of 
contraceptive pills can significantly reduce some mental 
disorders and mood-related to PMS such as depression, sad and 
crying, sobering up and anger. These findings are consistent 
with the results of some studies such as Shahpoorian and 
Collins but with the Adiguzel and Kues studies, it is somewhat 
consistent that perhaps this difference concerns the instrument 
for measuring these mental states, the degree of accuracy of 
participants to answer questions and the sample size of the 
research.11-14 In this study, it was found that the majority of 
girls participating in the program experienced a clear change in 
mood symptoms associated with PMS. The WHO, the 
prevalence of mood changes in the mood of PMS looking like 
irritability, sleepiness and, depression, it is related to ethnicity 
and race as in Indonesian women, 23% and 73% in Muslim 
women in Yugoslavia were reported that the reason for this 
contradiction in the findings can be attributed to this issue that 
in the present study, the research community did not have 
much diversity in terms of ethnicity and most of them were 
Fars.15,16 The study also showed that 65.5% of the students had 
signs and symptoms of PMS. This finding was consistent with 
the results of some studies conducted in Iran. The study of 
Nurjah,17 which reported a prevalence of PMS among female 
students of Tarbiat Modarres university, 67%. In the study of 
Talaei and et al.,18 the prevalence of PMS among students of 
the Mashhad university of medical sciences was 48.4% and in 
the study of Alavi and et al.,19 in southern Iran, the prevalence 
of PMS among medical students of Bandar Abbas medical 
university was 40.1%. Studies in neighboring countries have 
also reported a lower incidence of PMS compared with our 
study results. Among the studies in Balah et al., in Saudi 
Arabia, the prevalence of PMS among Malek Faisal university 
students was about 30.6%.20 In the study of Neissar et al., in 
Pakistan, the prevalence of PMS in medical students was about 
10%.21 In the meantime, the results of some studies in other 
countries such as the study by Rapkin et al., in Brazil22 and the 
study by Allen et al., in Nigeria23 coincided with the results of 
this study. In the Farahani study, which was conducted to 
compare the prevalence and severity of PMS in both athletic 
and non-athlete women, the prevalence of PMS was 33.4% in 
female athletes and 32% in control group.24 In this study, the 
severity of PMS was also studied, based on the findings, 48.8% 
of the units had mild PMS, 34.7% moderate and 16.5% severe 
PMS. In the study of Fotokian et al., in Tehran, the severity of 
PMS was 62% mild, 36% moderate and dysfunctional 
premenstrual dysfunction was only 2%.25 The results of this 
study about the severity of PMS are similar to most previous 
studies. In the present study, there was no significant 
relationship between the prevalence of PMS and the mean 
BMI. Maharaj et al., in their study considered weight and body 
mass index to be effective in the prevalence of symptoms of 
PMS.26 In the present study, there was no significant difference 
in the status of marital status with PMS, but in the Endicott and 
Kialashaki study, there was a significant correlation between 
the prevalence of PMS and marital status.27,28 Different results 
in the present study may be attributed to different statistical 
populations and different evaluation and diagnostic tools for PMS.  
Finally, the results of this study showed that although PMS 
prevalence among students is high, the use of contraceptive 
pills (in the present or the past) can clearly and meaningfully 
reduce some of the mood symptoms associated with PMS like 
depression, sadness, and crying, groaning and anger. This 
syndrome has a significant negative effect on women's 
emotions and function, prevalence and identification of 
predisposing factors of premenstrual syndrome and control of 
its effective factors can play a major role in preventing the 
severity of this disorder and improving the health of students.29-30 
Limitations that the researchers encountered in this study 
were; 1) no tendency to complete the data form, 2) no clinical 
investigation was done for assessing the emotional and 
psychological symptoms of PMS, 3) no equals of cases and 
controls in two groups. Of course, researchers have tried to 
control this limitation with regular follow-up and detailed 
explanations on how to complete this form. 
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